<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>RENVELAÂ - sevelamer carbonateÂ tablet, film coatedÂ </strong><br>KAISER FOUNDATION HOSPITALS<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Renvela safely and
        effectively. See full prescribing information for Renvela.<br><br> Renvela (sevelamer
        carbonate) Tablet, Film Coated for Oral use<br> Initial U.S. Approval: 2000 </div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><ul><li>Dosage and Administration (<a href="#d926ff32-cca5-40dc-b8b7-c6e4b672a3e2">2</a>)Â (08/2009)</li></ul></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><ul><li>Renvela<span class="Sup">Â®</span> is a phosphate binder
                                        indicated for the control of serum phosphorus in patients
                                        with <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span> on dialysis. (<a href="#f6da9301-4c3e-45d4-a0e7-f3e792bc306d">1</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<ul>
<li>Starting dose of RenvelaÂ is 0.8 orÂ 1.6
                                        grams administered orally three times per day with meals.
                                            (<a href="#acb1c866-38d7-4d4e-8bf3-16a0b73bfed3">2.1</a>)</li>
<li>TitrateÂ byÂ 0.8 gÂ per meal in
                                        two week intervals as needed to obtain serum phosphorus
                                        target (3.5 to 5.5 mg/dL). (<a href="#acb1c866-38d7-4d4e-8bf3-16a0b73bfed3">2.1</a>)</li>
<li>
                                    	Switch gram-for-gram among sevelamer formulations. Further titration may be 
                                    necessary to achieve desired phosphorus levels. (<a href="#acb1c866-38d7-4d4e-8bf3-16a0b73bfed3">2.1</a>)</li>
</ul>
<br>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li>Tablets: 800 mg (<a href="#c13a018b-d395-44b4-96ed-eaae5f187569">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul><li>
                                      <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Bowel obstruction</span>.
                                      (<a href="#d069bcc1-54f7-4b59-b610-d72701a1fcf9">4</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul><li>
                                      The safety and efficacy of Renvela in patients with
                                      <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">swallowing disorders</span>, severe GI motility
                                      disorders including severe <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, or major GI tract
                                      surgery have not been established. Uncommon cases of <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">bowel obstruction</span> and perforation have been reported 
                                      (<a href="#d30d35cd-2daf-492c-a7ce-82717a5b74a3">5.1</a>)</li></ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul>
<li>
                                      Most of the safety experience is with sevelamer tablets. The most
                                      frequently occurring adverse reactions in a short term
                                      study with sevelamer carbonate tablets (8-week cross-over) study were:
                                      <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (3%) and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (3%). (<a href="#e49f7fe1-b48b-4624-b4be-c682b42f6bd5">6.1</a>) In a short term study of sevelamer carbonate powder,
                                      adverse events were similar to those reported for sevelamer carbonate tablets. In long-term studies with
                                        sevelamer hydrochloride, which contains the same active
                                        moiety as sevelamer carbonate, the most common adverse
                                        events included: <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (22%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>
                                        (20%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (19%), <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>
                                        (16%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (9%), <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>
                                        (8%) and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (8%). (<a href="#e49f7fe1-b48b-4624-b4be-c682b42f6bd5">6.1</a>)</li>
<li>Cases of <span class="product-label-link" type="condition" conceptid="4258683" conceptname="Fecal impaction">fecal impaction</span> and, less commonly, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>, bowel
                                        obstruction and <span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">bowel perforation</span> have been reported.
                                            (<a href="#e0f5a715-d613-4c78-8bf0-4acd5229826f">6.2</a>)</li>
</ul>
<p class="Highlighta"><span class="Bold"><span class="Emphasis">To report SUSPECTED ADVERSE REACTIONS, contact Genzyme Corporation at 1-800-847-0069 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span></span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>
                                      Sevelamer decreases the bioavailability of ciprofloxacin by
                                      approximately 50%. (<a href="#c082194a-fbbb-4703-9f64-f5934a978938">7.1</a>)</li>
<li>
                                      Sevelamer did
                                      not alter the pharmacokinetics of single doses of digoxin,
                                      warfarin, enalapril, metoprolol, or
                                      iron.Â (<a href="#ad127c60-def4-43cd-981a-be8f5c7f83f2">7</a>)</li>
<li>
                                      When administering an oral medication where a reduction in
                                      the bioavailability of that medication would have a
                                      clinically significant effect on its safety or efficacy, administer the
                                      drug at least one hour before or three hours after Renvela, and monitor 
                                      blood levels of the drug. (<a href="#c86d3831-7532-461c-a76e-5fd3bb7e43a0">7.7</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 2/2010</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 General Dosing Information</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Use Caution in Patients with Gastrointestinal
                                Disorders</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Monitor Serum Chemistries</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Monitor for Reduced Vitamins D, E, K (clotting factors) and
                                Folic Acid Levels</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Ciprofloxacin</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Digoxin</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Warfarin</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Enalapril</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Metoprolol</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Iron</a></h2>
<h2><a href="#section-7.7" class="toc">7.7 Other Concomitant Drug Therapy</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Developmental Toxicity</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Cross-Over Study of Sevelamer Carbonate (Renvela<span class="Sup">Â®</span>)
                                800 mg Tablets and Sevelamer Hydrochloride (Renagel<span class="Sup">Â®</span>) 800
                                mg Tablets</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Cross-Over Study of Sevelamer Carbonate (Renvela<span class="Sup">Â®</span>)
                                Powder and Sevelamer Hydrochloride (Renagel<span class="Sup">Â®</span>)
                                Tablets</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Sevelamer Hydrochloride Versus Active-Control, Cross-Over
                                Study in Hemodialysis Patients</a></h2>
<h2><a href="#section-13.4" class="toc">14.4 Sevelamer Hydrochloride Versus Active-Control in
                                Hemodialysis Patients</a></h2>
<h2><a href="#section-13.5" class="toc">14.5 Sevelamer Hydrochloride Versus Active-Control in Peritoneal
                                Dialysis Patients</a></h2>
<h2><a href="#section-13.6" class="toc">14.6 Once a Day Versus Three Times a Day Dosing </a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Dosing</a></h2>
<h2><a href="#section-15.2" class="toc">17.2 Adverse Reactions</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Renvela<span class="Sup">Â®</span> (sevelamer carbonate) is indicated
                            for the control of serum phosphorus in patients with chronic kidney
                            disease (CKD) on dialysis.Â  </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">
                          Because of the rapid reaction with the hydrochloric acid in the stomach,
                          the dosing of Renvela powder or tablet is anticipated to be similar to that of the
                          sevelamer hydrochloride salt or tablet.
                        </p>
<br><div class="Section" data-sectionCode="42229-5">
<a name="section-2.1"></a><p></p>
<h2>2.1 General Dosing Information</h2>
<p class="First">Renvela should be given three times a day with meals.</p>
<p><span class="Italics"><span class="Emphasis">Patients Not Taking a
                                            Phosphate Binder.</span></span> Â The recommended starting dose of Renvela is
                                    0.8 to 1.6 g with meals based on serum phosphorus
                                        level. <a href="#c74578f0-3gyf-67fc-a3c4-4937gf23f4eb">Table1</a> provides recommended starting doses of Renvela
                                    for patients not taking a phosphate binder.</p>
<p><span class="Italics"><span class="Emphasis"></span></span></p>
<a name="c74578f0-3gyf-67fc-a3c4-4937gf23f4eb"></a><table>
<caption><span>Table 1. Starting Dose for Dialysis Patients Not Taking
                                        a Phosphate Binder</span></caption>
<colgroup>
<col align="center">
<col align="center">
<col align="center">
</colgroup>
<thead class="Botrule Lrule Rrule Toprule"><tr class="Last">
<th class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">Serum
                                                  PhosphorusÂ </span></span></th>
<th class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">Renvela<span class="Sup">Â®</span> 800 mg
                                                  TabletÂ </span></span></th>
<th class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold"><span class="Emphasis">Renvela
                                                  Powder</span></span>Â </th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center">Â &gt; 5.5 and &lt; 7.5 mg/dL</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 1
                                                tablet three times daily with meals</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 0.8 g three times daily with meals</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center">â‰¥
                                                7.5 mg/dL</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2 tablets three
                                                times daily with meals</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.6 g three
                                                times daily with meals</td>
</tr>
</tbody>
</table>
<br><p><span class="Italics"><span class="Emphasis">Switching from Sevelamer Hydrochloride Tablets.</span></span> Â For patients switching from sevelamer
                                  hydrochloride tablets to sevelamer carbonate tablets or powder, use the same 
                                  dose in grams.Â  Further titration may be necessary to achieve desired 
                                  phosphorus levels. The highest daily dose of sevelamer carbonate 
                                  studied was 14Â grams in CKD patients on dialysis. 
                                </p>
<p><span class="Italics"><span class="Emphasis">
                                          Switching between Sevelamer Carbonate Tablets and Powder.
                                        </span></span>
                                      Use the same dose in grams. Further titration may be necessary 
                                      to achieve desired phosphorus levels.
                                  </p>
<p><span class="Italics"><span class="Emphasis">
                                         Switching from Calcium Acetate. 
                                        </span></span>
                                     In a study in 84 CKD patients on
                                    hemodialysis, a similar reduction in serum phosphorus was seen
                                    with equivalent doses (approximately mg for mg) of sevelamer
                                    hydrochloride and calcium acetate. <a href="#c74579p0-3sdf-67fc-a3c4-4920gf23f4eb">Table
                                        2</a> gives recommended starting doses of Renvela
                                    based on a patientâ€™s current calcium acetate dose. </p>
<a name="c74579p0-3sdf-67fc-a3c4-4920gf23f4eb"></a><table>
<caption><span>Table 2. Starting Dose for Dialysis Patients Switching
                                        From Calcium Acetate to Renvela</span></caption>
<colgroup>
<col align="center">
<col align="center">
<col align="center">
</colgroup>
<thead class="Botrule Lrule Rrule Toprule"><tr class="Last">
<th class="Botrule Lrule Rrule Toprule" align="center">Â Calcium Acetate 667 mg<br>(Tablets per
                                                meal)</th>
<th class="Botrule Lrule Rrule Toprule" align="center">Renvela<span class="Sup">Â®</span> 800 mg
                                                Tablet<br>(Tablets per meal)Â </th>
<th class="Botrule Lrule Rrule Toprule" align="center">Renvela
                                                PowderÂ </th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center">1
                                                tablet</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1
                                                tablet</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.8 g</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">2
                                                tablets</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2
                                                tablets</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.6 g</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center">3
                                                tablets</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3
                                                tabletsÂ </td>
<td class="Botrule Lrule Rrule Toprule" align="center">2.4 g</td>
</tr>
</tbody>
</table>
<p><span class="Italics"><span class="Emphasis">Dose Titration for All Patients Taking Renvela.
                                    </span></span>Titrate the Renvela dose by 0.8 g TID with meals at two-week intervals as necessary with the goal of
                                  controlling serum phosphorus within the target range.
                                </p>
<p>Based on clinical studies, the average prescribed daily
                                    dose of sevelamer carbonate is approximately 7.2 g per
                                    day.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Tablets: 800 mg white oval, film-coated, compressed tablets
                            imprinted with â€œRENVELA 800â€?</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Renvela is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">bowel obstruction</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2>5.1 Use Caution in Patients with Gastrointestinal
                                Disorders</h2>
<p class="First">The safety of Renvela has not been established in
                                    patients with <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">swallowing disorders</span>, severe
                                    gastrointestinal (GI) motility disorders including severe
                                    <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, or major GI tract surgery. Uncommon cases of bowel 
                                    obstruction and perforation have been reported.
                                </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2"></a><p></p>
<h2>5.2 Monitor Serum Chemistries</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> and chloride levels should be
                                    monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3"></a><p></p>
<h2>5.3 Monitor for Reduced Vitamins D, E, K (clotting factors) and
                                Folic Acid Levels</h2>
<p class="First">In preclinical studies in rats and dogs, sevelamer
                                    hydrochloride, which contains the same active moiety as
                                    sevelamer carbonate, reduced vitamins D, E, and K (coagulation
                                    parameters) and folic acid levels at doses of 6â€‘10
                                    times the recommended human dose. In short-term clinical trials,
                                    there was no evidence of reduction in serum levels of vitamins.
                                    However, in a one-year clinical trial, 25-hydroxyvitamin D
                                    (normal range 10 to 55 ng/mL) fell from 39 Â± 22 ng/mL
                                    to 34 Â± 22 ng/mL (p&lt;0.01) with sevelamer
                                    hydrochloride treatment. Most (approximately 75%)
                                    patients in sevelamer hydrochloride clinical trials received
                                    vitamin supplements, which is typical of patients on
                                    dialysis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely
                                    varying conditions, adverse reaction rates observed in the
                                    clinical trials of a drug can not be directly compared to rates
                                    in the clinical trials of another drug and may not reflect the
                                    rates observed in practice.</p>
<p>There are limited data on the safety of Renvela. However,
                                    based on the fact that it contains the same active ingredient as
                                    the hydrochloride salt, the adverse event profiles of the two
                                    salts should be similar. In a cross-over study in hemodialysis
                                    patients with treatment durations of eight weeks each and no
                                    washout the adverse reactions on sevelamer carbonate tablets
                                    were similar to those reported for sevelamer
                                    hydrochloride.Â In another cross-over study in
                                    hemodialysis patients, with treatment durations of four weeks
                                    each and no washout between treatment periods, the adverse
                                    reactions on sevelamer carbonate powderÂ were similar to
                                    those reported for sevelamer hydrochloride.</p>
<p>In a parallel design study of sevelamer hydrochloride
                                    with treatment duration of 52 weeks, adverse reactions reported
                                    for sevelamer hydrochloride (n=99) were similar to those
                                    reported for the active-comparator group (n=101). Overall
                                    adverse reactions among those treated with sevelamer
                                    hydrochloride occurring in &gt; 5% of patients
                                    included: <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (22%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (20%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>
                                    (19%), <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span> (16%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>
                                    (9%), <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span> (8%) and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>
                                    (8%). A total of 27 patients treated with sevelamer and
                                    10 patients treated with comparator withdrew from the study due
                                    to adverse reactions. </p>
<p>Based on studies of 8-52 weeks, the most common reason
                                    for withdrawal from sevelamer hydrochloride was gastrointestinal
                                    adverse reactions (3-16%).</p>
<p>In one hundred and forty-three peritoneal dialysis
                                    patients studied forÂ 12 weeks using sevelamer
                                    hydrochloride, most adverse reactions were similar to adverse
                                    reactions observed in hemodialysis patients. The most frequently
                                    occurring treatment emergent serious adverse reaction was
                                    <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span> (8 reactions in 8 patients [8%] in the
                                    sevelamer group and 2 reactions in 2 patients [4%] on
                                    active-control). Thirteen patients (14%) in the
                                    sevelamer group and 9 patients (20%) in the
                                    active-control group discontinued, mostly for gastrointestinal
                                    adverse reactions. Patients on peritoneal dialysis should be
                                    closely monitored to ensure the reliable use of appropriate
                                    aseptic technique with the prompt recognition and management of
                                    any signs and symptoms associated with <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">
                                Because these reactions are reported voluntarily from a population of uncertain 
                                size, it is not always possible to reliably estimate their frequency or to 
                                establish a causal relationship to drug exposure.
                              </p>
<p>The following adverse reactions have been identified
                                    during post-approval use of sevelamer hydrochloride, which has
                                    the same active moiety as sevelamer carbonate: <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>,
                                    <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4258683" conceptname="Fecal impaction">fecal impaction</span>, and uncommon cases of <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>,
                                    <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, and <span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">intestinal perforation</span><span class="Italics"><span class="Emphasis">.</span></span> Appropriate medical management should be given to
                                    patients who develop <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> or have worsening of existing
                                    <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> to avoid severe complications.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">
                          Sevelamer carbonate has been studied in human drug-drug interaction studies 
                          with warfarin and digoxin. Sevelamer hydrochloride, which contains the same 
                          active moiety as sevelamer carbonate, has been studied in human drug-drug interaction
                          studies with ciprofloxacin, digoxin, warfarin, enalapril, metoprolol and
                          iron.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<h2>7.1 Ciprofloxacin</h2>
<p class="First">In a study of 15 healthy subjects, a co-administered
                                    single dose of 2.8 grams of sevelamer hydrochloride decreased
                                    the bioavailability of ciprofloxacin by approximately
                                    50%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2>7.2 Digoxin</h2>
<p class="First">In 19 healthy subjects receiving 2.4 grams of sevelamer
                                    hydrochloride three times a day with meals for 2 days, sevelamer
                                    did not alter the pharmacokinetics of a single dose of
                                    digoxin.</p>
<p>
                                In 18 healthy subjects receiving 9.6 grams of sevelamer carbonate once daily,
                                sevelamer did not alter the pharmacokinetics of a single dose of digoxin.
                              </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<h2>7.3 Warfarin</h2>
<p class="First">
                                  In 14 healthy subjects receiving 2.4 g of sevelamer
                                  hydrochloride three times a day with meals, sevelamer did not alter 
                                  the pharmacokinetics of a single dose of warfarin.
                                 </p>
<p>
                                In 14 healthy subjects receiving 9.6 grams of sevelamer carbonate once 
                                daily with meal, sevelamer did not alter the pharmacokinetics of a single 
                                dose of warfarin.
                              </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4"></a><p></p>
<h2>7.4 Enalapril</h2>
<p class="First">In 28 healthy subjects a single 2.4 gram dose of
                                    sevelamer hydrochloride did not alter the pharmacokinetics of a
                                    single dose of enalapril.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.5"></a><p></p>
<h2>7.5 Metoprolol</h2>
<p class="First">In 31 healthy subjects a single 2.4 gram dose of
                                    sevelamer hydrochloride did not alter the pharmacokinetics of a
                                    single dose of metoprolol.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.6"></a><p></p>
<h2>7.6 Iron</h2>
<p class="First">In 23 healthy subjects, a single 2.8 gram dose of
                                    sevelamer hydrochloride did not alter the absorption of a single
                                    oral dose of iron as 200 mg exsiccated ferrous sulfate
                                    tablet.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.7"></a><p></p>
<h2>7.7 Other Concomitant Drug Therapy</h2>
<p class="First">
                                  There are no empirical data on avoiding drug interactions
                                  between Renvela and most concomitant drugs. During postmarketing
                                  experience, very rare cases of increased thyroid stimulating
                                  hormone (TSH) levels have been reported in patients
                                  co-administered sevelamer hydrochloride and levothyroxine.
                                  Monitor TSH levels and signs of <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> in
                                  patients receiving both medications.</p>
<p>
                                  When administering an oral medication where a reduction
                                  in the bioavailability of that medication would have a
                                  clinically significant effect on its safety or efficacy, there is
                                  no information that suggests a dosing regimen that would be universally
                                  appropriate for all drugs. One may, however, administer the
                                  drug one hour before or three hours after Renvela, and when important, monitor
                                  blood levels of the drug. Patients taking anti-arrhythmic
                                  medications for the control of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> and anti-<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>
                                  medications for the control of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders were excluded
                                  from the clinical trials.
                                </p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category C: There are no adequate and well-controlled 
                                studies in pregnant women.  Sevelamer products should be used during pregnancy 
                                only if the potential benefit justifies the potential risk to the fetus.
                                </p>
<p>
                                  The effect of sevelamer
                                  hydrochloride on the absorption of vitamins and other nutrients
                                  has not been studied in pregnant women. Requirements for
                                  vitamins and other nutrients are increased in pregnancy. In
                                  pregnant rats given doses of sevelamer hydrochloride during
                                  organogenesis, reduced or irregular ossification of fetal bones,
                                  probably due to a reduced absorption of fat-soluble vitamin D,
                                  occurred at a dose approximately equal to the maximum clinical trial
                                  dose of 13 g on a body surface area basis. In pregnant rabbits given
                                  oral doses of sevelamer hydrochloride by gavage during organogenesis,
                                  an increase of early resorptions occurred at dose approximately twice 
                                  the maximum clinical trial dose on a body surface area basis
                                  <span class="Italics"><span class="Emphasis"><span class="Italics"><span class="Emphasis">[see </span></span><a href="#e0as5cc1-0f66-4d63-ac17-ad83e8666ece">
                                                Nonclinical Toxicology (13.2)</a><span class="Italics"><span class="Emphasis">]</span></span></span></span>.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">
                                  No sevelamer hydrochloride treatment-related effects on
                                  labor and delivery were seen in animal studies <span class="Italics"><span class="Emphasis"><span class="Italics"><span class="Emphasis">[see </span></span><a href="#f4aad622-04d7-4778-8d51-4557b56b0d8a">Nonclinical Toxicology (13)</a><span class="Italics"><span class="Emphasis">]</span></span></span></span>. The effects of sevelamer carbonate on labor and delivery 
                                  in humans is unknown.
                              </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and efficacy of Renvela has not been
                                    established in pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of Renvela did not include sufficient
                                    numbers of subjects aged 65 and over to determine whether they
                                    respond differently from younger subjects. Other reported
                                    clinical experience has not identified differences in responses
                                    between the elderly and younger patients. In general, dose
                                    selection for an elderly patient should be cautious, usually
                                    starting at the low end of the dosing range.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Sevelamer hydrochloride, which contains the same active moiety as
                            sevelamer carbonate, has been given to normal healthy volunteers in
                            doses of up to 14 grams per day for eight days with no adverse effects.
                            In CKD patients on dialysis, the maximum dose studied was 14 grams of
                            sevelamer carbonate and 13 grams of sevelamer hydrochloride. There are
                            no reports of overdosage with sevelamer carbonate or sevelamer
                            hydrochloride in patients. Since sevelamer is not absorbed, the risk of
                            systemic toxicity is low.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">The active ingredient in<span class="Bold"><span class="Emphasis">Â </span></span>Renvela is sevelamer carbonate, a polymeric amine that binds
                            phosphate and is meant for oral administration. It was developed as a
                            pharmaceutical alternative to sevelamer hydrochloride
                                (Renagel<span class="Sup">Â®</span>). Sevelamer carbonate is an anion
                            exchange resin, with the same polymeric structure as sevelamer
                            hydrochloride, in which carbonate replaces chloride as the counterion.
                            While the counterions differ for the two salts, the polymer itself, the
                            active moiety involved in phosphate binding, is the same.</p>
<p>Renvela (sevelamer carbonate) is known chemically as
                                poly(allylamine-<span class="Underline"><span class="Emphasis">co</span></span>-N,Nâ€™-diallyl-1,3-diamino-2-hydroxypropane)
                            carbonate salt. Sevelamer carbonate is hygroscopic, but insoluble in
                            water. The structure is represented in <a href="#a736615e-9d8c-4037-9b2b-6739ccc0d3ab">Figure
                                1</a>.</p>
<p><span class="Bold"><span class="Emphasis">Figure 1. Chemical Structure of
                                    Sevelamer Carbonate </span></span></p>
<p><img alt="Chemical Structure of Sevelamer Carbonate " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6178c669-a2e5-4a82-9ca2-7dfef56b63b9&amp;name=renvela-figure-1.jpg"></p>
<p>a, b = number of primary amine
                            groupsÂ Â Â Â Â a + b = 9<br>c
                            = number of crosslinking
                            groupsÂ Â Â Â Â Â Â Â Â Â Â 
                            c = 1<br>m = large number to indicate extended polymer
                            network</p>
<p><span class="Bold"><span class="Emphasis">Renvela<span class="Sup">Â®</span> Tablets:
                                </span></span> Each film-coated tablet of Renvela contains 800 mg of
                            sevelamer carbonate on an anhydrous basis. The inactive ingredients are
                            hypromellose, diacetylated monoglycerides, microcrystalline cellulose,
                            sodium chloride and zinc stearate. The tablet imprint contains iron
                            oxide black ink.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span> (CKD) retain phosphorus and
                            can develop <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span>. When the product of serum calcium and
                            phosphorus concentrations (Ca x P) exceeds 55
                                mg<span class="Sup">2</span>/dL<span class="Sup">2</span>, there is an increased risk that
                            ectopic calcification will occur. <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">Hyperphosphatemia</span> plays a role in the
                            development of secondary <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span> in <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>. </p>
<p>Treatment of <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span> includes reduction in dietary
                            intake of phosphate, inhibition of intestinal phosphate absorption with
                            phosphate binders, and removal of phosphate with dialysis. Sevelamer
                            carbonate taken with meals has been shown to control serum phosphorus
                            concentrations in patients with CKD who are on dialysis.</p>
<div class="Section" data-sectionCode="43679-0">
<a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Renvela contains sevelamer carbonate, a non-absorbed
                                    phosphate binding crosslinked polymer, free of metal and
                                    calcium. It contains multiple amines separated by one carbon
                                    from the polymer backbone. These amines exist in a protonated
                                    form in the intestine and interact with phosphate molecules
                                    through ionic and hydrogen bonding. By binding phosphate in
                                    theÂ gastrointestinal tract and decreasing absorption,
                                  sevelamer carbonate lowers the phosphate concentration in the
                                  serum (serum phosphorus).</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">In addition to effects on serumÂ phosphorus
                                    levels, sevelamer hydrochloride has been shown to bind bile
                                    acids <span class="Italics"><span class="Emphasis">in vitro</span></span> and <span class="Italics"><span class="Emphasis">in vivo</span></span> in experimental animal models. Bile acid binding by
                                    ion exchange resins is a well-established method of lowering
                                    blood <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>. Because sevelamer binds bile acids, it may
                                    interfere with normal fat absorption and thus may reduce
                                    absorption of fat soluble vitamins such as A, D and K. In
                                    clinical trials of sevelamer hydrochloride, both the mean total
                                    and LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> declined by 15-31%. This effect is
                                    observed after 2 weeks. Triglycerides, HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and
                                    albumin did not change.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">A <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> balance study using <span class="Sup">14</span>C-sevelamer
                                    hydrochloride, in 16 healthy male and female volunteers showed
                                    that sevelamer hydrochloride is not systemically absorbed. No
                                    absorption studies have been performed in patients with renal
                                    disease.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Standard lifetime carcinogenicity bioassays were
                                    conducted in mice and rats. Rats were given sevelamer
                                    hydrochloride by diet at 0.3, 1, or 3 g/kg/day. There was an
                                    increased incidence of urinary bladder transitional cell
                                    <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papilloma</span> in male rats of the high dose group (human equivalent
                                    dose twice the maximum clinical trial dose of 13 g). Mice
                                    received dietary administration of sevelamer hydrochloride at
                                    doses of up to 9 g/kg/day (human equivalent dose 3 times the
                                    maximum clinical trial dose). There was no increased incidence
                                    of tumors observed in mice.</p>
<p>In an <span class="Italics"><span class="Emphasis">in vitro</span></span> mammalian cytogenetic test with metabolic activation,
                                    sevelamer hydrochloride caused a statistically significant
                                    increase in the number of structural chromosome aberrations.
                                    Sevelamer hydrochloride was not mutagenic in the Ames bacterial
                                    mutation assay.</p>
<p>Sevelamer hydrochloride did not impair the fertility of
                                    male or female rats in a dietary administration study in which
                                    the females were treated from 14 days prior to mating through
                                    gestation and the males were treated for 28 days prior to
                                    mating. The highest dose in this study was 4.5 g/kg/day (human
                                    equivalent dose 3 times the maximum clinical trial dose of 13
                                    g).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2"></a><p></p>
<h2>13.2 Developmental Toxicity</h2>
<p class="First">
                        In pregnant rats given dietary doses of 0.5, 1.5 or 4.5 g/kg/day of sevelamer 
                        hydrochloride during organogenesis, reduced or irregular ossification of fetal 
                        bones, probably due to a reduced absorption of fat-soluble vitamin D, occurred 
                        in mid- and high-dose groups (human equivalent doses approximately equal to and
                        3.4 times the maximum clinical trial dose of 13 g). In pregnant rabbits 
                        given oral doses of 100, 500 or 1000 mg/kg/day of sevelamer hydrochloride by gavage 
                        during organogenesis, an increase of early resorptions occurred in the high-dose group 
                        (human equivalent dose twice the maximum clinical trial dose).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The ability of sevelamer to control serum phosphorus in CKD
                            patients on dialysis was predominantly determined from the effects of
                            the hydrochloride salt to bind phosphate. Six clinical trials used
                            sevelamer hydrochloride andÂ two clinical trials used sevelamer
                            carbonate. The sevelamer hydrochloride studies include one double-blind,
                            placebo-controlled 2-week study (sevelamer N=24); two open-label,
                            uncontrolled, 8-week studies (sevelamer N=220) and three
                            active-controlled open-label studies with treatment durations of 8 to 52
                            weeks (sevelamer N=256). The sevelamer carbonate studies include one
                            double-blind, active-controlled, cross-over study with two 8-week
                            treatment periods using sevelamer carbonate tablets (N=79) and one
                            open-label, active-controlled, cross-over study with two 4-week
                            treatment periods using sevelamer carbonate powder (N=31).Â 
                            Five of the active-controlled studies are described here (two sevelamer
                            carbonate and three sevelamer hydrochloride studies).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<h2>14.1 Cross-Over Study of Sevelamer Carbonate (Renvela<span class="Sup">Â®</span>)
                                800 mg Tablets and Sevelamer Hydrochloride (Renagel<span class="Sup">Â®</span>) 800
                                mg Tablets</h2>
<p class="First">Stage 5 CKD patients on hemodialysis were entered into a
                                    five-week sevelamer hydrochloride run-in period and 79 patients
                                    received, in random order, sevelamer carbonate 800 mg tablets
                                    and sevelamer hydrochloride 800 mg tablets for eight weeks each,
                                    with no intervening washout. Study dose during the cross-over
                                    period was determined based on the sevelamer hydrochloride dose
                                    during the run-in period on a gram per gram basis.
                                    TheÂ phosphorus levels at the end of each of the two
                                    cross-over periods were similar. Average actual daily dose was 6
                                    g/day divided among mealsÂ for both treatments.
                                    Thirty-nine of those completing the cross-over portion of the
                                    study were entered into a two-week washout period during which
                                    patients were instructed not to take any phosphate binders; this
                                    confirmed the activity of sevelamer in this study.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2"></a><p></p>
<h2>14.2 Cross-Over Study of Sevelamer Carbonate (Renvela<span class="Sup">Â®</span>)
                                Powder and Sevelamer Hydrochloride (Renagel<span class="Sup">Â®</span>)
                                Tablets</h2>
<p class="First">Stage 5 CKD patients on hemodialysis were entered into a
                                    four-week sevelamer hydrochloride run-in period and 31 patients
                                    received, in random order, sevelamer carbonate powder and
                                    sevelamer hydrochloride tablets for four weeks each with no
                                    intervening washout. Â Study dose during the cross-over
                                    period was determined based on the sevelamer hydrochloride dose
                                    during the run-in period on a gram per gram basis.Â  The
                                    phosphorus levels at the end of each of the two cross-over
                                    periods were similar.Â  Average actual daily dose was
                                    6.0 g/day divided among meals for sevelamer carbonate powder and
                                    6.4 g/day divided among meals for sevelamer hydrochloride
                                    tablets.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.3"></a><p></p>
<h2>14.3 Sevelamer Hydrochloride Versus Active-Control, Cross-Over
                                Study in Hemodialysis Patients</h2>
<p class="First">Eighty-four CKD patients on hemodialysis who were
                                    hyperphosphatemic (serum phosphorus &gt; 6.0 mg/dL)
                                    following a two-week phosphate binder washout period were
                                    randomized in a cross-over design to receive in random order
                                    sevelamer hydrochloride and active-control for eight weeks each.
                                    Treatment periods were separated by a two-week phosphate binder
                                    washout period. Patients started on treatment three times per
                                    day with meals. Over each eight-week treatment period, at three
                                    separate time points the dose of sevelamer hydrochloride could
                                    be titrated up to control serum phosphorus, the dose of
                                    active-control could also be altered to
                                    attainÂ phosphorus control. Both treatments
                                    significantly decreased mean serum phosphorus by about 2 mg/dL
                                        (<a href="#b1f35045-a160-4d85-8d7e-d0f706c420a4">Table 4</a>).</p>
<br><br><br><a name="b1f35045-a160-4d85-8d7e-d0f706c420a4"></a><table>
<caption><span>Table 4. Mean Serum Phosphorus (mg/dL) at Baseline and
                                        Endpoint</span></caption>
<colgroup>
<col align="left">
<col align="left">
<col align="left">
</colgroup>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Â Â p&lt;0.0001, within
                                                  treatment group
                                                  comparison</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">Sevelamer
                                                  Hydrochloride<br>(N=81) </span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">Active
                                                  Control<br>(N=83) </span></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">Baseline at End of Washout</td>
<td class="Botrule Lrule Rrule Toprule" align="center">8.4</td>
<td class="Botrule Lrule Rrule Toprule" align="center">8.0</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left">Change from Baseline at Endpoint<br>(95%
                                                Confidence Interval)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">-2.0<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>Â Â </p>
<p>(-2.5, -1.5)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">-2.1<a href="#footnote-1" class="Sup">*</a>Â Â </p>
<p>(-2.6, -1.7)</p>
</td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="Emphasis">FigureÂ 2. Cumulative percentage of patients (Y-axis) attaining a phosphorus change from baseline (mg/dL) at least as great as the value of the X-axis. A shift to the left of a curve indicates a better response. </span></span></p>
<p>Â <img alt="Cumulative percentage of patients (Y-axis) attaining a phosphorus change from baseline (mg/dL) at least as great as the value of the X-axis. A shift to the left of a curve indicates a better response." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6178c669-a2e5-4a82-9ca2-7dfef56b63b9&amp;name=renvela-figure-2.jpg"></p>
<p>Average daily sevelamer hydrochloride dose at the end of
                                    treatment was 4.9 g (range of 0.0 to 12.6 g).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.4"></a><p></p>
<h2>14.4 Sevelamer Hydrochloride Versus Active-Control in
                                Hemodialysis Patients</h2>
<p class="First">Two hundred CKD patients on hemodialysis who were
                                    hyperphosphatemic (serum phosphorus &gt; 5.5 mg/dL)
                                    following a two-week phosphate binder washout period were
                                    randomized to receive sevelamer hydrochloride 800 mg tablets
                                    (N=99) or an active-control (N=101). At week 52, using
                                    last-observation-carried-forward, sevelamer and active-control
                                    both significantly decreased mean serum phosphorus (<a href="#ce55327c-5e89-42c9-80bb-653a2d868f23">Table
                                        5</a>).</p>
<br><br><br><a name="ce55327c-5e89-42c9-80bb-653a2d868f23"></a><table>
<caption><span>Table 5.Â  Mean Serum Phosphorus (mg/dL) and
                                        Ion Product at Baseline and Change from Baseline to End of
                                        Treatment</span></caption>
<colgroup>
<col align="left">
<col align="left">
<col align="left">
</colgroup>
<thead class="Botrule Lrule Rrule Toprule"><tr class="Last">
<th class="Botrule Lrule Rrule Toprule" align="left"></th>
<th class="Botrule Lrule Rrule Toprule" align="center">Sevelamer<br>Â HCl<br>(N=94)</th>
<th class="Botrule Lrule Rrule Toprule" align="center">Active-ControlÂ <br>(N=98)</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">Phosphorus<br>Baseline<br>Change from
                                                  Baseline at <br>Endpoint</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7.5<br><br>-2.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7.3<br><br>-1.8</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">Ca x Phosphorus Ion
                                                  Product<br>Baseline<br>Change from Baseline
                                                  at<br>Endpoint</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">70.5<br><br>-19.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">68.4<br><br>-14.2</p></td>
</tr>
</tbody>
</table>
<p>Sixty-one percent of sevelamer hydrochloride patients and
                                    73% of the control patients completed the full 52 weeks
                                    of treatment. </p>
<p><a href="#MM410">Figure 3</a>, a plot of
                                    the phosphorus change from baseline for the completers,
                                    illustrates the durability of response for patients who are able
                                    to remain on treatment.</p>
<p><span class="Bold"><span class="Emphasis">Figure 3. Mean Phosphorus
                                            Change from Baseline for Patients who Completed 52 Weeks
                                            of Treatment </span></span></p>
<p><img alt="Mean Phosphorus Change from Baseline for Patients who Completed 52 Weeks of Treatment " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6178c669-a2e5-4a82-9ca2-7dfef56b63b9&amp;name=renvela-figure-3.jpg"></p>
<p>Average daily sevelamer hydrochloride dose at the end of
                                    treatment was 6.5 g (range of 0.8 to 13 g).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.5"></a><p></p>
<h2>14.5 Sevelamer Hydrochloride Versus Active-Control in Peritoneal
                                Dialysis Patients</h2>
<p class="First">One hundred and forty-three patients on peritoneal
                                    dialysis who were hyperphosphatemic (serum phosphorus &gt;
                                  5.5 mg/dL) following a two-week phosphate binder washout period
                                  were randomized to receive sevelamer hydrochloride (N=97)
                                    or active-control (N=46) open label for 12 weeks. Average daily
                                    sevelamer hydrochloride dose at the end of treatment was 5.9 g
                                    (range 0.8 to 14.3 g). Thirteen patients (14%) in the
                                    sevelamer group and 9 patients (20%) in the
                                    active-control group discontinued, mostly for gastrointestinal
                                    adverse reactions. There were statistically significant changes
                                    in serum phosphorus (p&lt;0.001) for sevelamer hydrochloride
                                    (-1.6 mg/dL from baseline of 7.5 mg/dL), similar to the
                                    active-control.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.6"></a><p></p>
<h2>14.6 Once a Day Versus Three Times a Day Dosing </h2>
<p class="First">
                        Stage 5 CKD patients on hemodialysis with a serum phosphate level of &gt; 5.5 mg/dL 
                        after washout from baseline therapies were randomized in a 2:1 ratio to receive 
                        either sevelamer carbonate powder once-daily (N=144) or sevelamer hydrochloride 
                        as a tablet with the dose divided TID (N=73) for 24 weeks. The initial dose for 
                        the two groups was 4.8 g/day.  At the end of the study, the total daily dose was 
                        6.2 Â± 2.6 g/day of sevelamer carbonate powder QD and 6.7 Â± 3.0 g/day of sevelamer 
                        hydrochloride tablets TID. A greater percentage of subjects on the once daily dose 
                        than TID regimen discontinued therapy prematurely, 35% versus 15%.  The reasons for 
                        discontinuation were largely driven by adverse events and withdrawal of consent in 
                        the once daily dosing regimen.  Serum phosphate levels and calcium-phosphate product 
                        were better controlled on the TID regimen than on the QD regimen.  Mean serum phosphorus 
                        decreased 2.0 Â± 1.8 mg/dL for sevelamer carbonate powder QD and 2.9 Â± 1.3 mg/dL for 
                        sevelamer hydrochloride tablets TID.
                        </p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Tablets: Renvela<span class="Sup">Â®</span> 800 mg Tablets are supplied
                            as white oval, film-coated, compressed tablets, imprinted with
                            â€œRENVELA 800â€?, containing 800 mg of sevelamer
                            carbonate on an anhydrous basis, microcrystalline cellulose,
                            hypromellose, diacetylated monoglycerides, sodium chloride, and zinc
                            stearate.</p>
<p>1 Box Unit Dose of 30 ct 800 mg Tablets (NDC 0179-0043-70)</p>
<p><span class="Bold"><span class="Emphasis">Storage: </span></span>Store at 25Â°C (77Â°F): excursions permitted
                            to 15-30Â°C (59-86Â°F).<br>[See USP controlled room
                            temperature]<br>Protect from moisture.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.1"></a><p></p>
<h2>17.1 Dosing</h2>
<p class="First">
                                   Inform patients to take Renvela as directed
                                   with meals and adhere to their prescribed
                                   diets.
                                 </p>
<p>
                                For patients using an oral medication where a reduction 
                                in the bioavailability of that medication would have a 
                                clinically significant effect on its safety or efficacy,
                                advise the patient to take the drug at least one hour 
                                before or three hours after Renvela but blood tests may 
                                be necessary to determine if there is a significant 
                                interaction between the drugs.
                              </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.2"></a><p></p>
<h2>17.2 Adverse Reactions</h2>
<p class="First">Renvela may cause <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> that if left untreated,
                                    may lead to severe complications. Patients should be cautioned
                                    to report new onset or worsening of existing <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>
                                    promptly to their physician.</p>
<p></p>
<p>RenvelaÂ®</p>
<p>sevelamer carbonate</p>
<p>tablets</p>
<p>800 mg</p>
<p>30 film-coated tablets in 1 Box, Unit Dose NDC 0179-0043-70</p>
<p>Rx Only</p>
<br><p>Manufactured by:</p>
<p>Genzyme Ireland Ltd.</p>
<p>For: Genzyme Corporation</p>
<p>500 Kendall Street</p>
<p>Cambridge, MA 02142 USA</p>
<br><p>Repackaged by:</p>
<p>KAISER FOUNDATION HOSPITALS</p>
<p>Livermore, CA 94551</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>Package Label</h1>
<p class="First"><img alt="Package Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6178c669-a2e5-4a82-9ca2-7dfef56b63b9&amp;name=Renvela-04.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>RENVELAÂ 		
					</strong><br><span class="contentTableReg">sevelamer carbonate tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0179-0043(NDC:58468-0130)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SEVELAMER CARBONATE</strong> (SEVELAMER) </td>
<td class="formItem">SEVELAMER CARBONATE</td>
<td class="formItem">800Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (5 MPA.S)</strong></td>
<td class="formItem">14.2Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (15 MPA.S)</strong></td>
<td class="formItem">14.2Â mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">157.8Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">3.2Â mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ZINC STEARATE</strong></td>
<td class="formItem">2.1Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (WHITE) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (OVAL) </td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">RENVELA;800</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0179-0043-70</td>
<td class="formItem">30  in 1 BOX, UNIT-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022127</td>
<td class="formItem">02/12/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>KAISER FOUNDATION HOSPITALS
							(053052619)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">KAISER FOUNDATION HOSPITALS</td>
<td class="formItem"></td>
<td class="formItem">053052619</td>
<td class="formItem">repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>db5fcaa7-4f01-4491-8aab-c6b8147dacee</div>
<div>Set id: 6178c669-a2e5-4a82-9ca2-7dfef56b63b9</div>
<div>Version: 5</div>
<div>Effective Time: 20110831</div>
</div>
</div>Â <div class="DistributorName">KAISER FOUNDATION HOSPITALS</div></p>
</body></html>
